CG MedTech breaks ground on new orthopedic implant plant in Uijeongbu to boost global production capacity

CG MedTech, a Korea-based orthopedic implant research and manufacturing company, said it has held a groundbreaking ceremony for its new production facility in Uijeongbu, Gyeonggi Province, last Friday.

The new facility will be built on a land area of 11,321 square meters, with a total floor space of 2,299 square meters. Once operational, CG MedTech expects the site to triple its current annual production capacity of metallic orthopedic implants from 200,000 to over 600,000 units. The expansion will include advanced systems and equipment aimed at streamlining production processes.

In addition, the company plans to introduce mass-production infrastructure for patient-specific 3D-printed medical devices, bolstering its capabilities in precision manufacturing and further enhancing its competitiveness in the global market.

The plant is also expected to serve as a strategic hub for CG MedTech’s mid-to-long-term plans to expand into CDMO (contract development and manufacturing organization) services for spinal and dental implants.

The company has previously supplied products to global medtech giants such as Zimmer Biomet and LDR through OEM contracts. Leveraging this experience, CG MedTech intends to offer more structured and scalable custom manufacturing solutions to international partners.

Looking ahead, CG MedTech aims to establish a dedicated CDMO subsidiary that will serve as a foundry-style platform for non-manufacturing companies—including design-focused firms, hospital networks, and marketing-led global enterprises—seeking outsourced production capabilities.

The company will gradually incorporate advanced automated systems integrated with artificial intelligence to enhance its ability to deliver customized, high-quality products efficiently.

The new facility also aligns with the Uijeongbu city government’s broader plan to promote advanced industrial development. In March last year, the city signed a memorandum of understanding with CG Bio, CG MedTech’s parent company, to cooperate on expanding local biopharma and medtech infrastructure and creating regional employment opportunities.

“This new plant marks the starting point of CG MedTech’s journey toward becoming a global medical device leader equipped with cutting-edge technologies and strong profitability,” CG MedTech CEO Yu Hyun-seung said. “Our long-term vision is to evolve beyond traditional manufacturing into a ‘total medical solution company’ that combines advanced technology with personalized care.”

Through the company’s future CDMO subsidiary and other strategic initiatives, it aims to strengthen our global presence, Yu added.